Q-omics provides the consensus-scored NFKBIB profile across patient tissues and cancer cell-line models. NFKBIB expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NFKBIB is differentially expressed in 15, with the highest sampling consensus in STAD. Additionally, NFKBIB RNA expression shows 19,458 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and STAD as cancer lineages where NFKBIB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NFKBIB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NFKBIB survival associations across molecular data types. NFKBIB RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NFKBIB RNA expression–survival associations across cancer types. High NFKBIB expression shows unfavorable associations in ACC, LGG and OV, but favorable associations in SCLC, SARC and CHOL. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NFKBIB RNA expression.
This table summarizes NFKBIB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NFKBIB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NFKBIB shows higher tumor expression in STAD, COAD, HNSC, LIHC, BLCA and UCEC. The STAD box plot shows higher NFKBIB RNA expression in tumor versus normal tissue (log2 FC = +0.959, t-test p < 0.001).
This table shows molecular features associated with NFKBIB in patient tissues and cancer cell lines. In patient samples, NFKBIB shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NFKBIB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
